TLR9 Induces Colitis-associated Colorectal Carcinogenesis by Regulating NF-κB Expression Levels

Overview

Journal Oncol Lett

Specialty Oncology

Date 2020 Sep 1

PMID 32863923

Citations 11

Authors

Qingtian Luo

Ling Zeng

Chaotao Tang

Zhendong Zhang

Youxiang Chen

Chunyan Zeng

Affiliations

Soon will be listed here.

Abstract

Chronic colorectal inflammation has been associated with colorectal cancer (CRC); however, its exact molecular mechanisms remain unclear. The present study aimed to investigate the effect of Toll-like receptor 9 (TLR9) on the development of colitis-associated CRC (CAC) through its regulation of the NF-κB signaling pathway. By using a CAC mouse model and immunohistochemistry, the present study discovered that the protein expression levels of TLR9 were gradually upregulated during the development of CRC. In addition, the expression levels of TLR9 were revealed to be positively correlated with NF-κB and Ki67 expression levels. In vitro, inhibiting TLR9 expression levels using chloroquine decreased the cell viability, proliferation and migration of the CRC cell line HT29, and further experiments indicated that this may occur through downregulating the expression levels of NF-κB, proliferating cell nuclear antigen and Bcl-xl. In conclusion, the findings of the present study suggested that TLR9 may serve an important role in the development of CAC by regulating NF-κB signaling.

Citing Articles

Toll-like receptors in health and disease.

Wang K, Huang H, Zhan Q, Ding H, Li Y MedComm (2020). 2024; 5(5):e549.

PMID: 38685971 PMC: 11057423. DOI: 10.1002/mco2.549.

Advances in molecular mechanisms of inflammatory bowel disease‑associated colorectal cancer (Review).

Wang Z, Chang Y, Sun H, Li Y, Tang T Oncol Lett. 2024; 27(6):257.

PMID: 38646499 PMC: 11027113. DOI: 10.3892/ol.2024.14390.

Gut Microbiota, Inflammatory Bowel Disease, and Cancer: The Role of Guardians of Innate Immunity.

Giambra V, Pagliari D, Rio P, Totti B, Di Nunzio C, Bosi A Cells. 2023; 12(22).

PMID: 37998389 PMC: 10669933. DOI: 10.3390/cells12222654.

Toll-like receptor-guided therapeutic intervention of human cancers: molecular and immunological perspectives.

Mukherjee S, Patra R, Behzadi P, Masotti A, Paolini A, Sarshar M Front Immunol. 2023; 14:1244345.

PMID: 37822929 PMC: 10562563. DOI: 10.3389/fimmu.2023.1244345.

Senolytic Treatment Improve Small Intestine Regeneration in Aging.

Luo Q, Ye Y, Guo W, Zhu Q, Wang S, Li N Aging Dis. 2023; 15(4):1499-1507.

PMID: 37815904 PMC: 11272202. DOI: 10.14336/AD.2023.0920.

References

Kinzler K, Vogelstein B . Lessons from hereditary colorectal cancer. Cell. 1996; 87(2):159-70. DOI: 10.1016/s0092-8674(00)81333-1. View

Soh J, Jo S, Lee H, Do E, Hwang S, Park S . Immunoprofiling of Colitis-associated and Sporadic Colorectal Cancer and its Clinical Significance. Sci Rep. 2019; 9(1):6833. PMC: 6497720. DOI: 10.1038/s41598-019-42986-1. View

Capece D, Verzella D, Tessitore A, Alesse E, Capalbo C, Zazzeroni F . Cancer secretome and inflammation: The bright and the dark sides of NF-κB. Semin Cell Dev Biol. 2017; 78:51-61. DOI: 10.1016/j.semcdb.2017.08.004. View

Eaden J, Abrams K, Mayberry J . The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48(4):526-35. PMC: 1728259. DOI: 10.1136/gut.48.4.526. View

Gemoll T, Kollbeck S, Karstens K, Ho G, Hartwig S, Strohkamp S . EB1 protein alteration characterizes sporadic but not ulcerative colitis associated colorectal cancer. Oncotarget. 2017; 8(33):54939-54950. PMC: 5589632. DOI: 10.18632/oncotarget.18978. View

Fan Y, Liu B . Expression of Toll-like receptors in the mucosa of patients with ulcerative colitis. Exp Ther Med. 2015; 9(4):1455-1459. PMC: 4353785. DOI: 10.3892/etm.2015.2258. View

Taniguchi K, Karin M . NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018; 18(5):309-324. DOI: 10.1038/nri.2017.142. View

Cai Y, Huang J, Xing H, Li B, Li L, Wang X . Contribution of FPR and TLR9 to hypoxia-induced chemoresistance of ovarian cancer cells. Onco Targets Ther. 2019; 12:291-301. PMC: 6314315. DOI: 10.2147/OTT.S190118. View

Tian Y, Xu Q, Sun L, Ye Y, Ji G . Short-chain fatty acids administration is protective in colitis-associated colorectal cancer development. J Nutr Biochem. 2018; 57:103-109. DOI: 10.1016/j.jnutbio.2018.03.007. View

10.

Mohamed F, Al-Jehani R, Minogue S, Andreola F, Winstanley A, Olde Damink S . Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int. 2014; 35(3):1063-76. DOI: 10.1111/liv.12626. View

11.

Nojiri K, Sugimoto K, Shiraki K, Tameda M, Inagaki Y, Kusagawa S . The expression and function of Toll-like receptors 3 and 9 in human colon carcinoma. Oncol Rep. 2013; 29(5):1737-43. DOI: 10.3892/or.2013.2322. View

12.

Hudert C, Weylandt K, Lu Y, Wang J, Hong S, Dignass A . Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci U S A. 2006; 103(30):11276-81. PMC: 1544078. DOI: 10.1073/pnas.0601280103. View

13.

Havenar-Daughton C, Kolumam G, Murali-Krishna K . Cutting Edge: The direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. J Immunol. 2006; 176(6):3315-9. DOI: 10.4049/jimmunol.176.6.3315. View

14.

Dong T, Yi T, Yang M, Lin S, Li W, Xu X . Co-operation of α-galactosylceramide-loaded tumour cells and TLR9 agonists induce potent anti-tumour responses in a murine colon cancer model. Biochem J. 2015; 473(1):7-19. DOI: 10.1042/BJ20150129. View

15.

Xue Q, Cao L, Chen X, Zhao J, Gao L, Li S . High expression of MMP9 in glioma affects cell proliferation and is associated with patient survival rates. Oncol Lett. 2017; 13(3):1325-1330. PMC: 5403257. DOI: 10.3892/ol.2017.5567. View

16.

Schmoll H, Wittig B, Arnold D, Riera-Knorrenschild J, Nitsche D, Kroening H . Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol. 2014; 140(9):1615-24. PMC: 4131138. DOI: 10.1007/s00432-014-1682-7. View

17.

Zeng C, Zhan Y, Huang J, Chen Y . MicroRNA‑7 suppresses human colon cancer invasion and proliferation by targeting the expression of focal adhesion kinase. Mol Med Rep. 2015; 13(2):1297-303. DOI: 10.3892/mmr.2015.4643. View

18.

Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H . A Toll-like receptor recognizes bacterial DNA. Nature. 2000; 408(6813):740-5. DOI: 10.1038/35047123. View

19.

Akira S, Takeda K, Kaisho T . Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001; 2(8):675-80. DOI: 10.1038/90609. View

20.

Gao C, Kozlowska A, Nechaev S, Li H, Zhang Q, Hossain D . TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy. Cancer Res. 2013; 73(24):7211-21. PMC: 3917779. DOI: 10.1158/0008-5472.CAN-13-1314. View